Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease

Zhaoyi Chen, Hansi Zhang, Yi Guo, Thomas J George, Mattia Prosperi, William R Hogan, View ORCID ProfileZhe He, Elizabeth A Shenkman, Fei Wang, View ORCID ProfileJiang Bian
doi: https://doi.org/10.1101/2020.06.03.20121491
Zhaoyi Chen
1Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hansi Zhang
1Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Guo
1Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas J George
2Hematology & Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mattia Prosperi
3Department of Epidemiology, College of Public Health and Health Professions & College of Medicine, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William R Hogan
1Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhe He
4School of Information, Florida State University, Tallahassee, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhe He
Elizabeth A Shenkman
1Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Wang
5Department of Healthcare Policy and Research, Cornell University, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiang Bian
1Health Outcomes & Biomedical Informatics, University of Florida, Gainesville, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiang Bian
  • For correspondence: bianjiang@ufl.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

In this study, we explored the feasibility of using real-world data (RWD) from a large clinical research network to simulate real-world clinical trials of Alzheimer’s disease (AD). The target trial (i.e., NCT00478205) is a Phase III double-blind, parallel-group trial that compared the 23 mg donepezil sustained release with the 10 mg donepezil immediate release formulation in patients with moderate to severe AD. We followed the target trial’s study protocol to identify the study population, treatment regimen assignments, and outcome assessments, and to set up a number of different simulation scenarios and parameters. We considered two main scenarios: (1) a one-arm simulation: simulating a standard-of-care arm that can serve as an external control arm; and (2) a two-arm simulation: simulating both intervention and control arms with proper patient matching algorithms for comparative effectiveness analysis. In the two-arm simulation scenario, we used propensity score matching controlling for baseline characteristics to simulate the randomization process. In the two-arm simulation, higher SAE rates were observed in the simulated trials than the rates reported in original trial, and a higher SAE rate was observed in the 23mg arm than the 10 mg standard-of-care arm. In the one-arm simulation scenario, similar estimates of SAE rates were observed when proportional sampling was used to control demographic variables. In conclusion, trial simulation using RWD is feasible in this example of AD trial in terms of safety evaluation. Trial simulation using RWD could be a valuable tool for post-market comparative effectiveness studies and for informing future trials’ design. Nevertheless, such approach may be limited, for example, by the availability of RWD that matches the target trials of interest, and further investigations are warranted.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported in part by NIH grants R21AG061431 and UL1TR001427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved as exempt by the University of Florida IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data used in this work are available from the OneFlorida Clinical Research Consortium upon request and committee review.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 31, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease
Zhaoyi Chen, Hansi Zhang, Yi Guo, Thomas J George, Mattia Prosperi, William R Hogan, Zhe He, Elizabeth A Shenkman, Fei Wang, Jiang Bian
medRxiv 2020.06.03.20121491; doi: https://doi.org/10.1101/2020.06.03.20121491
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease
Zhaoyi Chen, Hansi Zhang, Yi Guo, Thomas J George, Mattia Prosperi, William R Hogan, Zhe He, Elizabeth A Shenkman, Fei Wang, Jiang Bian
medRxiv 2020.06.03.20121491; doi: https://doi.org/10.1101/2020.06.03.20121491

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1771)
  • Dentistry and Oral Medicine (239)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10816)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2961)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1934)
  • Health Policy (836)
  • Health Systems and Quality Improvement (746)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12528)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (88)
  • Nephrology (325)
  • Neurology (2811)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (599)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (869)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (339)
  • Psychiatry and Clinical Psychology (2649)
  • Public and Global Health (5384)
  • Radiology and Imaging (1018)
  • Rehabilitation Medicine and Physical Therapy (598)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)